Clinical Trials Logo

Papilloma clinical trials

View clinical trials related to Papilloma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT02632344 Active, not recruiting - Clinical trials for Recurrent Respiratory Papillomatosis

Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients

Start date: April 2016
Phase: Phase 2
Study type: Interventional

This research study is evaluating an immune modulatory agent as a possible treatment for patients with Recurrent Respiratory Papillomatosis (RRP) with significant disease involving the larynx, trachea, and/or lungs. The investigators will be using Pembrolizumab as the treating agent.

NCT ID: NCT02489617 Active, not recruiting - Clinical trials for Intraductal Papilloma Without Atypia

The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy

Start date: September 2015
Phase: N/A
Study type: Interventional

This research study is studying a surgical intervention to rule out the presence of cancer in participants that have been diagnosed with flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA) by core needle biopsy.

NCT ID: NCT02258659 Active, not recruiting - Clinical trials for Stage III Squamous Cell Carcinoma of the Oropharynx

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer

OPTIMA
Start date: September 22, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus (HPV)-related oropharyngeal cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, hydroxyurea, fluorouracil, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving nab-paclitaxel and carboplatin before chemoradiation may make the tumor smaller and reduce the amount of chemotherapy and radiation therapy needed. Assigning chemotherapy and radiation therapy based on response (response-based therapy) and giving patients who are responding well lower doses of treatment may help reduce the occurrence of side effects.

NCT ID: NCT02135419 Active, not recruiting - HIV Infection Clinical Trials

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

ANCHOR
Start date: September 24, 2014
Phase: Phase 3
Study type: Interventional

The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. The ANCHOR Data Safety Monitoring Board (DSMB) determined that the primary study endpoint was completed, based on the data and statistical analysis presented to them on 07SEP2021. In the post-randomization phase of this trial, all enrolled participants are offered treatment for HSIL and/or follow-up, at the participant's choice.

NCT ID: NCT01901770 Active, not recruiting - Healthy Clinical Trials

The Parents in Appalachia Receive Education Needed for Teen Project

PARENT
Start date: January 2012
Phase: N/A
Study type: Interventional

This clinical trial studies an educational intervention for parents and providers in increasing human papillomavirus (HPV) vaccination rates in younger girls in Ohio Appalachia. Educational interventions may be effective in increasing the number of participants whose daughters receive HPV vaccination.

NCT ID: NCT01898494 Active, not recruiting - Clinical trials for Stage III Squamous Cell Carcinoma of the Oropharynx

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

Start date: January 22, 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery.